Tempus AI Stocks Rally 22% as Merck-Moderna Cancer Vaccine Clears Phase 3 Trial
Tempus AI (TEM) shares climbed 22% on Wednesday after Merck and Moderna announced their Phase 3 INTerpath-001 study met its primary endpoint of keeping patients disease-free longer after surgery and a key secondary endpoint of reducing distant metastasis risk. The trial tested individualized mRNA th
LucasBennett·08-19 20:14
